{"id":"https://genegraph.clinicalgenome.org/r/3385b6a6-1151-4882-8ba7-67e33b09f526v2.0","type":"EvidenceStrengthAssertion","dc:description":"*SIK1* was first reported in relation to autosomal dominant developmental and epileptic encephalopathy (AD-DEE) in 2015 (Hansen et al., PMID: 25839329). SIK1 is a member of the AMP kinase (AMPK) subfamily and encodes salt-induced kinase 1, a serine/threonine protein kinase that contains a ubiquitin-associated (UBA) domain. The gene plays a role in the central nervous system, neuronal development, and a signal transduction pathway involved in nuclear regulation of gene expression (PMID: 25839329). \n\nFour missense variants and three nonsense variants reported in seven probands across two publications (PMIDs: 25839329, 35267137) have been included in this curation. All nonsense variants were downgraded because of functional evidence from Hansen et al. (PMID:25839329) suggesting that p.Glu347Ter, p.Gln614Ter, and p.Gln663Ter all generate a truncated form of SIK1 that is resistant to degradation. The mechanism of pathogenicity is unclear. In summary, there is limited evidence to support the relationship between SIK1 and autosomal dominant developmental and epileptic encephalopathy (AD-DEE). Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. \n\nThe gene-disease pair was originally evaluated by the Epilepsy GCEP on 10/2/2018 and reached a classification of limited. In 2021, this record went through administrative changes to update the disease term. Evidence was reevaluated on 5/7/2024 under SOP v.10.1. As a result of this reevaluation, the classification did not change and remains at limited. \n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/3385b6a6-1151-4882-8ba7-67e33b09f526","GCISnapshot":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975","calculatedEvidenceStrength":"Limited","changes":[{"id":"cg:sopChange"},{"id":"cg:newEvidence"},{"id":"cg:otherTextChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-05-07T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2024-12-09T17:45:12.513Z","role":"Publisher"}],"curationReasons":["RecurationNewEvidence","RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1617535-32d7-4b74-a383-2ef0261749e1","type":"EvidenceLine","dc:description":"Functional evidence from Hansen et al. (PMID:25839329) suggests that p.Glu347Ter generates a truncated form of SIK1 that is resistant to degradation. Additionally, this variant it did not affect SIK1 protein expression levels in patientâ€™s brain tissue.\n","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1617535-32d7-4b74-a383-2ef0261749e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/c0e8a75c-9e3c-4fce-a5ec-d6ebe875a42a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.1039G>T (p.Glu347Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/190106"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/e46b834b-a14a-46df-883a-40c2caa37591","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e46b834b-a14a-46df-883a-40c2caa37591_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/ed07be33-11d3-4981-80f3-3d37de761ff5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.1906G>A (p.Gly636Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/190109"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cc3e6703-3b63-4a24-8a11-cf194be42048","type":"EvidenceLine","dc:description":"Allele count of 14 in gnomAD v2.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc3e6703-3b63-4a24-8a11-cf194be42048_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35267137","allele":{"id":"https://genegraph.clinicalgenome.org/r/53c956f0-0e28-4617-80d4-7b11942e86bd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.880G>A (p.Ala294Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA321326772"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b99e121c-38ff-4b8f-940a-21252d54a4d4","type":"EvidenceLine","dc:description":"Functional evidence from Hansen et al. (PMID:25839329) suggests that p.Glu614Ter generates a truncated form of SIK1 that is resistant to degradation. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b99e121c-38ff-4b8f-940a-21252d54a4d4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/19e9bbf1-c3c9-4464-b573-6ae4ce2457e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.1840C>T (p.Gln614Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/190107"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c32e0b2c-7ebd-406f-a085-10b25927503b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c32e0b2c-7ebd-406f-a085-10b25927503b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/80213075-97fb-458e-ba47-70e5d2ebbcea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.3(SIK1):c.1231A>T (p.Ser411Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA410608450"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b04832b0-6236-4ac1-a754-43c1448ee1ab","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b04832b0-6236-4ac1-a754-43c1448ee1ab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/04eee871-6d7f-4bd2-97d2-7ca82499404d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.859C>A (p.Pro287Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/190105"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/b04832b0-6236-4ac1-a754-43c1448ee1ab_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When comparing the wild type SIK1 allele with the p.Pro287Thr variant, the variant was associated with abnormal neuronal morphology, significant decreases in mean neurite length, mean number of neurites and a significant increase in proximal branches (PMID: 27966542). ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/57bf499e-2df9-468c-ad77-79ac3b6bd384","type":"EvidenceLine","dc:description":"Functional evidence from Hansen et al. (PMID:25839329) suggests that p.Gln663Ter generates a truncated form of SIK1 that is resistant to degradation. ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57bf499e-2df9-468c-ad77-79ac3b6bd384_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25839329","allele":{"id":"https://genegraph.clinicalgenome.org/r/fd053d92-8463-4f38-8ac6-6fee009a2a9e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_173354.5(SIK1):c.1897C>T (p.Gln633Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/190108"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2.7},{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eb25ed3f-04d4-48c3-9de0-6add2961ebaf","type":"EvidenceLine","dc:description":"The Epilepsy GCEP decided not to score this paper as the evidence is not a direct link to the clinical phenotype. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6df837c5-4dc9-4347-8b14-af4ec844b437","type":"Finding","dc:description":"The level of MEF2 transcriptional activity was measured using Mef2 luciferase reporter to compare SIK1 variants to wild-type and the p.(Lys56Met) kinase-dead mutant. Expression of wild-type SIK1 robustly activated the Mef2-luc reporter. In fetal cortical neuronal cells, Western blot showed different MEF2C protein levels depending on SIK1 genotype.  Results indicate decreased MEF2C protein levels and decrease in MEF2C transcriptional activity in the presence of variants in SIK1.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27966542","rdfs:label":"SIK1 interacts with MEF2C","demonstrates":{"id":"obo:MI_0208"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4468120d-08e9-4acf-bd13-169c820d93ca","type":"EvidenceLine","dc:description":"The Epilepsy GCEP decided not to score this paper as the evidence is not a direct link to the clinical phenotype. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dce806d8-3a67-45ef-9f53-f441de4a046f","type":"FunctionalAlteration","dc:description":"In non-neuronal cells, Mef2 luciferase reporter assay performed in 293TN cells to evaluate the effect of SIK1 pathogenic sequence variations on Mef2c-based transcription, and variants expressed in primary human fetal cortical neurons to measure protein expression measured by Western blot.  In non-neuronal cells, epilepsy-causing SIK1 mutants were associated with a significant decrease in Mef2-luc reporter expression compared with wild-type. Western blot of neurons expressing truncating variants showed decreased MEF2C protein levels compared with wt. mRNA levels for ARC and other MEF2C target genes (NR4A1 (Nur77) and NRG1) showed significantly decreased expression in neurons at 20 weeks gestation.  Truncating SIK1 sequence variations led to abnormal MEF2C transcriptional activity and decreased MEF2C protein levels, and all 3 variants were associated with significantly decreased expression of ARC (activity-regulated cytoskeletal-associated) and other synaptic activity response element genes.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27966542","rdfs:label":"SIK1 variants disrupt MEF2C and downstream protein expressio"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/cd76888e-9502-48f3-af06-56f1ae5ed975_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/32635d8f-798b-46dc-a3f0-efbe50a7178b","type":"EvidenceLine","dc:description":"No spontaneous seizures were detected. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1287ffc-1d3f-4202-8dcd-0325e1c8d2cf","type":"Finding","dc:description":"In the mouse model, the seizures were triggered (not spontaneous)  ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35887274","rdfs:label":"Mouse model ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":0}],"evidenceStrength":"Limited","sequence":9477,"specifiedBy":"GeneValidityCriteria10","strengthScore":2.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/LIO4ilKN3wE","type":"GeneValidityProposition","disease":"obo:MONDO_0100062","gene":"hgnc:11142","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_cd76888e-9502-48f3-af06-56f1ae5ed975-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}